About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

24-hour IOP-lowering Effect of Brimonidine 0.1%

NCT00457795·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Allergan

Age

40–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

patients with open-angle glaucoma or ocular hypertension

You may not be if

allergy to brimonidine
inability to complete 24 hour stay for monitoring

The record

StatusCompleted

PhasePhase 4

Taking part15

StartedDec 2006

UpdatedNov 24, 2011

Conditions

Open-angle Glaucoma Ocular Hypertension

Where1

San Diego, California, United States

Clareo Health | 24-hour IOP-lowering Effect of Brimonidine 0.1%